NAV up 45.9% on a 54.5% portfolio return; revenue earnings retreated

NTA per share finished the year at £10.97. The trust swung from a £226.7m loss in FY20 to a £934.4m profit, with profit before tax growing 516.0% to £922.6m.

Investment income for the year was £59.9m, but the revenue earnings line measured per share (28.64p) was lower than the prior period's comparable revenue contribution, signalling pressure on the income component of total return. The ongoing charges ratio was 0.97%.

The board proposed total distributions of 29.0p per share (5.0p interim, 14.0p final, and a 10.0p special), up from 21.6p in FY20, with the increase entirely driven by the larger special dividend. Gross borrowings were unchanged at £100.0m and cash ended at £85.2m.

• The £947.7m total return on the portfolio sits against just £59.9m of investment income, which means the FY21 result is a function of fair-value movements in emerging-market equities rather than a step-up in distributable cash. That makes the NAV recovery vulnerable to the same fair-value mechanics in reverse.

• The enlarged distribution is not fully covered by revenue earnings. At a 29.0p total distribution and disclosed coverage of 86.7%, the trust is paying out more than its current-year revenue earnings generated. This matters because, absent a structural recovery in dividend income from underlying holdings, repeat-quantum special dividends would need to draw on accumulated revenue reserves or capital.

• The headline NPAT jump is clean on tax but flattered by base effects. The effective tax rate of 1.3% (FY20: -2.2%) is consistent with an investment trust structure where most capital gains are tax-exempt, so the small 3.9pp gap between PBT and NPAT growth is not a distortion. The 512.1% swing is, however, measured off a loss base; the more useful read is the absolute £2,591.3m of net assets and the 54.5% portfolio return.

The trust's stated benchmark is the MSCI Emerging Markets Index with net dividends reinvested; the supplied benchmark return figure looks implausible for a single year and should be cross-checked against the trust's own performance disclosure before any active-return conclusion is drawn.

What the release does support is that the year captured a strong cyclical recovery in emerging-market equities and that the trust converted that into a 54.5% portfolio total return and a 45.9% lift in net assets. What it does not support is any read on whether outperformance versus benchmark was material, or whether revenue earnings will recover enough to cover the elevated distribution rate next year.

The £934.4m profit is therefore high-quality as a measure of NAV accretion in the period, but it is not a reliable indicator of repeatable annual returns; emerging-market beta will determine the next several years' headline numbers more than anything in this release.

The income side is the softer point. Investment income of £59.9m supports an expense ratio of 0.97% comfortably, but revenue earnings covered only 86.7% of the 29.0p distribution. Operating cash inflow of £51.5m (FY20: £44.4m) was modestly higher, and cash on balance sheet was broadly stable at £85.2m against unchanged £100.0m of fixed-term debt, so the trust funded the larger total payout without balance-sheet stress this year — but the coverage gap is the line to watch.

This briefing cannot assess relative performance versus benchmark on a verified basis, the breakdown of revenue earnings by holding, or the trust's discount/premium to NAV.